Wingspan stent for symptomatic M1 XXXX of middle cerebral artery.

@entity1 @entity64 @entity63 @entity2500 @entity12705 @entity510 @entity661 @entity850 @entity4522
OBJECTIVE: Stent placement for @entity4522 has become an alternative treatment technique; however, stent placement for @entity2500 remains a technical and clinical challenge. Our purpose was to assess the safety and feasibility of Wingspan stent for @entity1 with symptomatic M1 @entity850 , and its initial effect on prevention of @entity63 events. METHODS: Fifty-three cases with recurrent @entity2500 resistant to medical therapy treated by self-expanding stent were reviewed retrospectively (average 58  18.5 years old, 19 @entity1 ). All @entity1 underwent angioplasty and stenting with the Gateway @entity661 , and advised follow-up with DSA or @entity12705 at 6th month. RESULTS: @entity1 had an average @entity850 ratio of 76.5  15.4% prior to the treatment. Of the 53 @entity1 , the technical success rate was 98.1% as a whole (52/53). The mean degree of @entity850 reduced from (76.5  15.4)% to (18.2  11.3)%. Complications associated with the procedure include @entity510 (1.89%) and occlusion (3.78%) occurred. During a follow-up of 6 months, there was no recurrence of transient @entity63 attack or @entity64 in 52 cases with successful stenting. Cerebral hemodynamics of MCA using transcranial Doppler monitoring were at normal level (<120 cm/s) in 41 follow-up @entity1 . The follow up angiography at 6 month post-procedure was conducted in 32 @entity1 and showed good patency in stented vessels. CONCLUSIONS: Wingspan stent for symptomatic @entity850 of middle cerebral artery is a safe and feasible procedure. It improves clinical outcome in the intermediate follow up, but its long-term effect remains to be further evaluated.
